| Product Unit Size | Cost | Quantity | Stock |
|---|
LY-3200882 is an inhibitor of TGFβR1. The TGF-β pathway is frequently deregulated in tumors, and plays an important role in the regulation of cell growth, differentiation, and apopsosis. Preliminary safety and efficacy studies suggest that LY-3200882 is for patients with certain advanced or metastatic cancers, for example it inhibits tumor growth in preclinical models of triple negative breast cancer.
| Cas No. | 1898283-02-7 |
|---|---|
| Purity | ≥98% |
| Formula | C24H29N5O3 |
| Formula Wt. | 435.53 |
| Chemical Name | LY-3200882 |
| IUPAC Name | 2-{4-[(4-{[1-Cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy}-2-pyridinyl)amino]-2-pyridinyl}-2-propanol |
| Synonym | LY 3200882, LY3200882 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Huaxing P., Saravanan P., et al. LY3200882, a novel, highly selective TGFβRI small molecule inhibitor. Cancer Research. 77(13 Suppl): Abstract nr 955.